INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inmune Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.54−0.03 (-1.91%)
Close on Oct 19, 2026
- Market cap
- $41.15M
- P/E (TTM)
- –
- Dividend yield
- –
Inmune Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Market Cap | $42.74M | $197.05M |
| Enterprise Value | $24.33M | $106.56M |
| PB Ratio | 2.10 | 2.14 |
| P/TBV Ratio | 2.10 | 2.46 |
Income (trailing twelve months)
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Operating Income | -$20.20M | -$21.44M |
| Net Income | -$18.42M | -$22.46M |
| EBITDA | -$20.20M | -$16.91M |
| EPS (Diluted) | -$0.69 | -$0.83 |
Returns
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -74.8% | -53.1% |
| Return on Assets (ROA) | -57.1% | -41.0% |
| Return on Capital Employed (ROCE) | -96.4% | -37.8% |
Growth
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -48.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 35.4% | 6.42% |
Balance sheet
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $18.41M | $62.42M |
| Net Cash (Debt) | $18.41M | $15.68M |
| Net Cash Per Share | $0.66 | $0.65 |
| Equity (Book Value) | $20.36M | $48.79M |
| Book Value Per Share | $0.73 | $1.36 |
| Tangible Book Value | $20.36M | $23.06M |
| Working Capital | $17.91M | $75.77M |
Financial position
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Current Ratio | 4.04 | 3.30 |
| Quick Ratio | 3.88 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.96M | -$12.35M |
Efficiency
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Profits Per Employee | -$3.07M | -$732.08K |
| Employee Count | 6 | 73 |
Dividends and yields
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Earnings Yield | -43.1% | -21.2% |
Shares
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Shares Outstanding | 27,753,800 | 59,128,900 |
| Shares Change (YoY) | 20.7% | 11.1% |
| Shares Change (QoQ) | 4.02% | 0.54% |
| Float | 23,128,800 | 48,744,500 |
| Shares Held by Insiders | 16.7% | 11.8% |
| Shares Held by Institutions | 15.7% | 59.4% |
Scores
| Measure | Inmune Bio | Industry median |
|---|---|---|
| Altman Z-Score | -8.98 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Inmune Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.